- 1 Article summary line: Descriptive and molecular epidemiology of leishmaniasis over a one-
- 2 year period in the United States
- 3 **Running title:** Molecular detection of leishmaniasis in the United States
- 4 **Keywords:** leishmaniasis; Leishmania; leishmaniasis, cutaneous; leishmaniasis, mucocutaneous;
- 5 leishmaniasis, visceral; polymerase chain reaction; epidemiology
- 7 **Title:** Windows into leishmaniasis epidemiology in the United States: September 2021 through
- 8 August 2022

9

13

17

20

- 10 **Authors:** Thao T. Truong, Karissa Crawford, Ichih Wang-McGuire, Kendal Jensen, Aisha
- Mushtaq, Nicole A.P. Lieberman, Frederick S. Buckner, Wesley C. Van Voorhis, Brad T.
- 12 Cookson, Stephen J. Salipante, and Joshua A. Lieberman[#]
- 14 **Affiliations:** University of Washington, Seattle, Washington, USA (T. Truong, K. Crawford, I.
- Wang-McGuire, K. Jensen, A. Mushtaq, N. Lieberman, F. Buckner, W. Van Voorhis, B.
- 16 Cookson, S. Salipante, J. Lieberman)
- 18 #Corresponding Author: Joshua A. Lieberman, joshuaal@uw.edu, Department of Laboratory
- 19 Medicine and Pathology, Box 357110, 1959 NE Pacific St, Seattle, WA 98195 □ 7110
- 21 **ORCIDS:** JAL 0000-0002-0376-1337; SJS 0000-0001-8355-6992; TTT 0000-0002-5856-324X,
- 22 NAPL 0000-0001-9334-8150; WCVV 0000-0001-6141-2015

Abstract

Leishmaniasis is a rare disease in the United States, with an estimated annual incidence of dozens of cases occurring primarily in travelers, migrants, and military personnel. True disease incidence is unknown, since leishmaniasis is not a nationally notifiable condition. Here, we describe the results of molecular leishmaniasis over a 1-year interval (September 2021 to August 2022) when our laboratory served as the primary national reference laboratory for molecular diagnosis of civilian leishmaniasis. We tested 218 specimens submitted from 36 states yielding 94/186 (50.5%) positive cases with species or species complex-level identification and 18 novel mini-exon alleles. Most species belonged to subgenus *Viannia* (75.6%) and associated with cutaneous or mucocutaneous disease. Cases were associated with recent travel (18.1%), travel timing unspecified (7.4%), migration (7.4%), remote travel (2.1%), military (1.1%), or unknown history (63.8%). These data illustrate the clinical utility of molecular testing for leishmaniasis and provide unique insight into disease epidemiology.

Introduction

Leishmania parasites are transmitted to humans by bites from infected phlebotomine sandflies. Over 20 Leishmania species are described and cause a wide spectrum of clinical disease in humans. Although leishmaniasis is considered a neglected tropical disease, it is endemic to 98 countries and its worldwide distribution is impacted by human conflict, travel, immigration, and displacement (1). Leishmania species endemic to the Eastern hemisphere have been geographically categorized as "Old World" Leishmania (OWL) whereas those endemic to the Western hemisphere have been termed "New World" Leishmania (NWL) (2). Most human infection is caused by species from one of two subgenera. The New World subgenus Viannia

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

includes L. braziliensis spp. complex and L. guyanensis spp. complex, which cause cutaneous and/or mucocutaneous lesions. Subgenus Leishmania includes Old World L. major, Old World L. tropica spp. complex, and New World L. mexicana spp. complex, which all cause cutaneous leishmaniasis (CL). The *Leishmania* subgenus additionally includes *L. donovani* (OWL) and *L.* infantum (OWL)/L. chagasi (NWL), which are associated with organotropic visceral leishmaniasis (VL), the most fatal clinical manifestation. Diagnostic testing methods include histopathology to visualize intracellular amastigote stage parasites, in vitro culturing from lesions, serology, and molecular detection of parasite DNA (3). However, molecular methods are considered most sensitive, and are often most rapid (2–5). The University of Washington (UW) reference laboratory developed and validated a polymerase chain reaction (PCR) and Sanger sequencing assay to detect and identify Leishmania from tissue and body fluid specimens. The approach interrogates the organism's multicopy miniexon gene using primers targeting regions conserved across Leishmania species (6). The amplified region is sufficiently diverse to allow taxonomic determination of species or species complex (6,7). Along with patient immune status, type and severity of clinical disease, and travel history, knowledge of the infecting *Leishmania* species helps determine the risk for mucocutaneous leishmaniasis (MCL), which can impact treatment and management (3). Leishmania has been considered endemic to the United States since 2015, after several reports of autochthonous CL (8–10). Previous studies of *Leishmania* infection epidemiology in the U.S. have been limited in scope and often lack species-level identification, comprising surveillance of armed forces members, case reports, and multicenter observational studies (11– 13). During September 2021 – July 2022, culture, serology, and molecular testing and identification of *Leishmania* species was temporarily discontinued at the U.S. Centers for

Disease Control and Prevention (CDC) as part of an agency-wide pause on clinical testing (14), leaving the UW diagnostic reference laboratory the only service providing molecular *Leishmania* testing to the general U.S. population during this period (3). This situation offers a unique and relatively unbiased opportunity to examine molecular testing results for patients with suspected leishmaniasis within the United States. Here, we present the largest survey of *Leishmania* testing in the U.S. performed to date, encompassing 94 positive patient cases with species-level identification from testing specimens from 186 patients submitted over a 1-year period. Our work lends significant insights into descriptive and molecular epidemiology of leishmaniasis in the U.S.

Materials and Methods

Assay Validation

We validated a PCR and Sanger sequencing assay targeting the *Leishmania* mini-exon gene (6) under the CLIA '88 regulatory framework and guidelines established by the Clinical Laboratory Standards Institute. Assay performance was assessed using 7 cultured isolates (axenic promastigote culture) and genomic DNA purchased from the American Type Culture Collection (ATCC 50129); 13 residual clinical specimens positive for *Leishmania* spp. by broad-range fungal PCR performed in our laboratory and/or by culture and molecular analysis at the CDC Parasitic Disease Branch; and 22 residual clinical specimens negative for *Leishmania* spp. but positive for other pathogens (Table S1). DNA extraction, sequence analysis, and case review were performed as previously described (15,16). Specimens were tested in technical duplicate with positive, negative, and inhibition control reactions. Assay performance was fully reproducible across 3 operators.

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

Patient Population The study cohort included all patients with leishmania testing performed at the UW Molecular Microbiology clinical diagnostic laboratory between the assay's initial offering on 9/1/2021 and 8/31/2022. The CDC referred leishmaniasis testing to the University of Washington from 10/2021 to 7/2022. Acceptable specimen types included fresh and formalinfixed paraffin-embedded (FFPE) tissue, body fluids, buffy coat preparations, and (with laboratory director approval) stain-positive peripheral blood. Demographic and Clinical Information Demographic data including sex, age, state from which specimen was submitted, dates of collection/submission, and specimen description/anatomic site were obtained from the laboratory information system. When available, clinical history, histopathology findings, and travel history were obtained from medical records including physician clinicopathologic consultations. Ethical Approval The study was approved by the UW IRB (STUDY00013877). Data Analysis Data were analyzed in R (version 4.2.1) (17). Maps and figures were generated using usmap, tidyverse, cowplot, and getree packages (18–21). "Cases" were defined as unique patients, regardless of the number of specimens tested. Chi-square tests were used to compare categorical variables using GraphPad QuickCalcs (22). Assembled mini-exon sequences were MAFFT aligned in Unipro Ugene v44.0 (23) with published reference sequences representing human-infecting species complexes and curated manually to consolidate mini-exon alleles exhibiting minor length variation. Trees were

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

generated by IO-Tree with automatic substitution model optimization (24) and visualized with ggtree (25). Data availability Sequences have been deposited to Genbank (accessions OR026045-OR026086) with metadata available in BioSample accessions SAMN35159702 - SAMN35159803 (BioProject PRJNA974035). Deidentified, patient-specific molecular data are available upon request with appropriate human subject approvals. **Results** Assay Validation. We determined assay performance for a PCR and Sanger sequencing assay targeting the Leishmania mini-exon gene (6) using extracted DNA from axenic promastigote culture and residual clinical specimens known to be positive for *Leishmania* spp. or common and/or morphologically similar pathogens (Table S1). The assay's 95% limit of detection (LOD) was established as 1 genome per reaction by testing serial dilutions of purified genomic DNA into testing matrix (Table S2). Sensitivity of testing for DNA extracted from cultured promastigote cell pellets, purified parasite DNA, and patient specimens was 90.5%. Species complex identification was fully concordant with CDC gold-standard testing. Specificity was 100%, with no cross-reactivity with human DNA or other tested pathogens (Table S1). Testing cohort. We clinically tested 218 specimens from 186 patients over the one-year period from September 2021 through August 2022. 94 patients (50.5%) had at least 1 specimen positive for Leishmania (Table 1). Specimens were submitted from 36 U.S. states and the territory of Puerto Rico, as well as Quebec, Canada and the Dominican Republic (Figure 1).

California, Florida, and Texas submitted the most cases for testing, with corresponding positivity

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

rates of 48.5% (16/33), 50.0% (8/16), and 41.2% (7/17) (Figure 1D). Overall case and specimen positivity rates were 50.5% and 47.7% over the study period (Figure 2A, Table 1, Table 2). The months with the highest case volumes were June, May, and February 2022 (Figure S1). Median test turnaround time was 3.19 days (IQR 1.32 - 3.91) from specimen receipt. Demographics of positive cases. Of patients testing positive for Leishmania, 59/94 (62.8%) were aged 20-59 and 19 (20.2%) were under the age of 18, including 11 under age 10 years (Table 1, Figure S2). Sixteen patients (17.0%) were over age 60, including 1 patient over 80 years (Table 1, Figure S2). More patients with leishmaniasis were male (63.8%) (Table 1). Travel history was unavailable for 60 positive cases (63.8%), while 17 (18.1%) had documented international travel to *Leishmania*-endemic regions within 6 months prior to testing. Two (2.1%) cases documented international travel >5 years prior to diagnosis, while 7 (7.4%) noted travel history without specifying timing. Twelve positive cases (12.8%) were associated with travel to Costa Rica (Table S3). There were 7 cases (7.4%) with a history of migration from endemic areas and 1 case (1.1%) from a military service member with L. major. Although we did not receive cases where the possibility of endemic infection was explicitly documented, we noted 2 cases positive for L. mexicana spp. complex from Texas, where that species is endemic, although travel information was not provided. Specimen characteristics. Despite expectations for DNA degradation, formalin-fixed paraffin-embedded (FFPE) specimens yielded a higher overall positivity rate than fresh tissue specimens: 60.7% of 107 specimens versus 35.1% of 111 specimens (P < 0.0002, Chi-square test; Figure 2B, Table 3) (26). Positivity rate was highest (100%) in cases where staining patterns suspicious for intracellular organisms were reported (Table 3). Cases where characteristic Leishmania amastigotes were noted on histopathology had the second highest positivity rate

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

(88.2%) (Table 3). Of the 2 cases that were histopathology positive but negative by molecular testing, one was instead positive for Staphylococcus aureus and the other for Histoplasma capsulatum by additional clinical molecular testing performed in our laboratory. The most commonly involved body sites were skin, representing 86 cases (91.5%), particularly from exposed areas: arms, legs, head, and neck (Figure 3A). Four positive cases (4.3%) were detected from 5 oropharyngeal specimens and identified as *L. braziliensis* spp. complex, two of which were recurrent infections (Table S4). Only one specimen collected from internal organ sites or body fluids potentially associated with visceral disease tested positive: a paraffin-embedded inguinal lymph node positive for *Leishmania donovani* spp. complex (Figure 3B and 3C). 22 patients had multiple specimens submitted. These included 13 positive cases and 9 negative cases (Table S4). Of the positive cases, 9 comprised specimen pairs collected less than 30 days apart. In 3 cases the initial specimen was positive, but subsequent specimens sent >30 days later were negative. One case involved multiple specimens collected 5 months apart that were positive for L. guyanensis spp. complex, having the same mini-exon sequence (Table S4). Two instances showed mini-exon sequence variation across different body sites: one case of L. braziliensis spp. complex in both an epiglottis and pharynx lesion and one case of L. guyanensis spp. complex in both an ear (helix) and shoulder lesion. Leishmania species and molecular epidemiology. Mini-exon sequencing provided adequate resolution (>80% bootstrap) to achieve species complex-level identification (Figure 4, Table 2). Of the 94 positive cases, 71 (75.5%) were subgenus *Viannia*. 53 (56.4%) were identified as L. guyanensis spp. complex, 17 (18.1%) as L. braziliensis spp. complex, and 1

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

(1.1%) as L. lainsoni spp. complex. Detected sequences included 18 previously unreported miniexon alleles (Table S5, BioProject 974035). We observed significant mini-exon sequence conservation within L. braziliensis. Two L braziliensis spp. complex alleles accounted for 10 of 17 cases (Lbr A-06, Lbr B-04) and were separated from each other by 3 polymorphisms. Sequence conservation across L. braziliensis and L. peruviana reference strains precluded resolution of these two species with two exceptions. Two mini-exon sequences, Lbr F and Lbr G, formed a clade (>95% bootstrap) with "Type 2" L. braziliensis mini-exon reference sequences (KF633199, MHOM/PE/03/LH2511; KF633195, MHOM/CO/90/LEM2216). Travel history was not available for Lbr F, while Lbr G had traveled to Peru. These Type 2 braziliensis sequences were detected once each. The two member species of the L. guyanensis spp. complex, L. guyanensis and L. panamensis, had nearly identical previously published mini-exon sequences, precluding identification to the species rank. A single mini-exon allele (Lgu_A-39) accounted for most L. guyanensis spp. complex cases (33/53), including 6 cases with identical sequences recovered in multiple lesions. The second most abundant allele (Lgu-B-07) accounted for 7 cases and was only distinguished from Lgu_A-39 by homopolymer length variation. The next two most abundant alleles (Lgu C-03, Lgu D-03) accounted for 6 additional cases. Nine cases (9.6%) were L. mexicana spp. complex and two alleles accounted for 7 of these (Lme A-04 and Lme B-03). The detected sequences formed a high-confidence clade with L. mexicana reference sequences (Figure 4). However, the mini-exon sequence (CP040130) from one recently completed, unpublished genome of *L. amazonensis*, UA301 (GCA_005317125.1) had 100% identity to multiple detected sequences. The UA301 mini-exon sequence thus defies

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

the otherwise clear separation of L. mexicana and L. amazonensis/L. garnhami into two clades that are well-resolved by mini-exon sequences (Figure 4). Fewer cases corresponded to OWL: 10 (10.6%) cases of L. tropica spp. complex and 3 (3.2%) L. major, one of which was from a military service member. Other patients positive for OWL include one patient who traveled to Yemen, one who had previously lived in and recently visited Tunisia, and one identified as an Afghan refugee (Table S3). Available clinical history for the one L. donovani spp. complex infection (1.1%) was not sufficient to determine its acquisition and molecular diagnosis could not resolve the organism to the species level. Thus, this case could represent either an infection with Old World species L. donovani or L. infantum, or infection with New World *L. chagasi/infantum*. Sequences within the *L. tropica* spp. complex included two potential subclades with >80% bootstrap support (Figure 4A-B). The remaining allele (Ltr_G-01) had 99.75% identity over 392 nucleotides to L. killicki (GenBank AY155504) and was derived from a patient who had lived in and recently visited Tunisia. This case was reported to the species rank given the geographic association with *L. killicki* (Figure 4A, Table S3) (27). The distribution of identified species paralleled the travel history in the 34 cases with documented exposures. Of these, 23 (67.6%) had traveled to or from North, Central, or South America (Table 2, Table S3). There were 7 known migration-related cases, including 6 NWL infections, comprising five L. guyanensis spp. complex; 1 L. braziliensis spp. complex. Four involved patients had traveled from Central and/or South America, while one had immigrated from West Africa, but did not have explicitly documented travel history to an endemic area. One patient from Afghanistan tested positive for *L. tropica* spp. complex (Table S3, Table S5).

Discussion

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

Our work describes molecular reference testing for *Leishmania* in the general U.S. population during a period where it was otherwise unavailable. This has provided a unique opportunity to compile a comprehensive, 1-year catalog of patient and pathogen characteristics that help approximate the incidence and epidemiology of infections in the U.S. In agreement with prior studies involving U.S. travelers, our case demographics reflect a slight male predominance at 63.8% (12,28–30). Also consistent with previous observations, positive cases were associated with recent travel to Central and South America, particularly Costa Rica, where there is a high incidence of leishmaniasis (Table 1, Table S2) (12,28,29,31). 11.7% of cases in this work were in children younger than 10 and 6.4% in the 10-18 age range, adding to reports of pediatric infection in the U.S. (12,13,29,32,33) Migration-related leishmaniasis has increased globally, but U.S.-specific data has been limited to sporadic case studies (28,34–37). This work identifies 7 cases (7.4% of all positive) of likely migration-related infection originating from multiple continents, highlighting a need for increased clinician awareness in this vulnerable population (Table 1, Table S3). Given that travel histories were not available for most (63.8%) cases, this likely underestimates the true disease burden in this group. Endemic infection with L. mexicana spp. complex has been documented in Texas and Oklahoma, but the provided clinical histories from our cases did not enable us to determine the probability of autochthonous leishmaniasis. CL is the most common clinical manifestation reported in recent U.S. studies. (11–13), and 91.5% of cases in this study were CL. We additionally detected L. braziliensis in 4 patients with mucosal disease, including two with relapsed MCL acquired during travel several years prior. In contrast, a prior case series and review by Murray et al. reported only 6 documented

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

civilian cases of MCL in the U.S from 1975-2020 (36). Our cohort may be enriched for MCL due to the high prevalence of subgenus *Viannia*, which accounted for 75% of all cases. Identification to species complexes within subgenus Viannia is clinically informative for treatment and monitoring, due to the associated risk of progression to MCL with most Viannia species (3). Within Viannia, mini-exon sequencing typically lacked resolution beyond the species complex level, particularly L. guyanensis spp. complex (Figure 4). Consistent with prior analyses (6), our assay could distinguish L. braziliensis Type 2 from L. peruviana (Figure 4). Most Type 1 L. braziliensis and L. peruviana couldn't be distinguished; clinically, this may overestimate a patient's risk of developing mucosal disease. Intriguingly, we identified a high-confidence clade of L. braziliensis Type 1 (KF633199, Lbr-B, Lbr-C) that may be separable from *L. peruviana* and an outlier sequence in *L. braziliensis* spp. complex (Lbr H) with 100% identity to the first reported L. braziliensis infection in Suriname (HE610677, Figure 4) (38). These emerging clades suggest additional mini-exon sequences from well-characterized strains could increase molecular diagnostic resolution, particularly in combination with detailed travel history. We note several patients with positive cutaneous specimens who traveled to multiple countries and were consequently at risk for infection from different *Leishmania* species. In such instances improved species-level identification would more accurately assess risk for progression to mucosal involvement (3). Visceral leishmaniasis cases are rare in the U.S. but have been documented in service members returning from endemic regions, and there are concerns for undetected asymptomatic infection and risk for reactivation in these veterans (11,12,39). In this series, only one case tested positive for L. donovani spp. complex, which is associated with visceral disease and was

consistent with our detection in a lymph node. In agreement with previous studies (6) our assay could not distinguish between *L. donovani* and *L. infantum/chagasi*.

Clinical and laboratory diagnosis of leishmaniasis can be challenging, and molecular methods are considered the most sensitive diagnostic modality (2,3). This work and others have demonstrated the utility of the mini-exon gene as a sensitive, specific, and effective target for distinguishing the major species complexes (6,7,40). Moreover, our assay readily detects infection from a variety of specimen types associated with CL, MCL, and VL, and has demonstrated good performance with FFPE specimens. With rapid turnaround times (~3 days), molecular testing and sequencing can effectively inform patient treatment and management.

We found that mini-exon sequencing is sufficient for identification of clinically relevant species complexes, supporting prior work showing that species identification from mini-exon analysis had comparable performance to multilocus sequence typing or single gene target assays (6,40). We successfully resolved *L. lainsoni* from other *Viannia* species, which has historically posed technical challenges (6). However, an important limitation is that most closely related species within each of the *L. donovani*, *L. guyanensis*, and *L. braziliensis* species complexes could not be resolved. This challenge is clinically relevant within *L. braziliensis* spp. complex, given the greater propensity of *L. braziliensis* for mucocutaneous spread relative to *L. peruviana* (41). Nevertheless, expanding publicly available mini-exon sequence records may enable more specific identification.

We identified 18 previously unreported mini-exon alleles, expanding the diversity of known sequences and highlighting opportunities to improve molecular species identification. Whole-genome sequencing will enable more accurate and specific identification, resolve technical artifacts, and identify co-infections (7). The challenges in resolving species within

complexes and unexpected findings from recently sequenced strains, such as *L. amazonensis* UA301 clading with *L. mexicana* strains, emphasize the evolutionary complexity of *Leishmania* species (42–44).

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

Although illuminating, there are several limitations to this study. First, our estimates of disease burden and the granularity of our demographic data are limited by the incompleteness of clinical information provided to our reference laboratory. This poses particular challenges in interpreting patients with multiple positive specimens, as prolonged PCR positivity does not necessarily reflect treatment failure (45). Second, it is likely that additional civilian cases were not tested at our laboratory, particularly after testing resumed at CDC during July 2022. Third, Leishmania testing remained available for Department of Defense personnel and contractors at the Walter Reed Army Institute of Research (WRAIR) during the study period (46); therefore, the single L. major case we detected in a U.S. armed forces personnel likely underrepresents disease burden. A survey by Stahlman et al documented over 2,000 cases in the U.S. Armed Forces from 2001-2016 but noted significantly fewer cases starting in 2011, with only 11 in 2015 (3,11,46). Finally, mini-exon sequence data have inherent limitations. The *Leishmania* mini-exon gene is comprised of 100-200 tandem repeats, which increases the risk of chimeric PCR artifacts (7) and masks low abundance sequence variants. Although our validation studies confirmed this issue did not interfere with the ability to discriminate between different species complexes, we are limited in making more refined phylogenetic inferences that would require more comprehensive whole-genome sequencing data.

Leishmaniasis remains challenging to recognize clinically, and we expect it is still underdiagnosed in the U.S. (2,12,13). Most state public health agencies do not require positive test notification, with the exception of Texas, and suboptimal reporting compliance has been

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

documented (13). Our study demonstrates that molecular testing by mini-exon sequencing provides clinically actionable species-level identification, and when considered in aggregate, suggests a significantly higher annual incidence in the U.S. than previously appreciated. The burden, distribution, and biology of this disease will continue to change with global travel, migration, and climate changes impacting parasite, vector, and host geography (47). This work highlights the role of molecular testing in enabling diagnostic laboratory professionals, providers, and public health agencies to track and appropriately treat this disease. Acknowledgements We are grateful to Stephanie Krieg, MLS(ASCP) and Dr. Dhruba SenGupta for their work establishing clinical assay in the laboratory information system (LIS) and integration with the electronic medical record; Dan Hoogestraat MB(ASCP) for assistance obtaining data from the LIS; and Dr. Noah Hoffman for helpful discussions of phylogenetic analysis. We thank our colleagues at the CDC Parasitic Disease Branch for referring testing to the University of Washington. **Biographical Sketch** Dr. Truong is a clinical microbiology and molecular microbiology laboratory director at UW Medicine. Her research interests include diagnostic stewardship and evaluating the clinical impact of rapid diagnostic technologies to improve patient care. References

- 1.Global leishmaniasis surveillance: 2019–2020, a baseline for the 2030 roadmap [Internet].
- 344 [cited 2022 Sep 13]. Available from: https://www.who.int/publications-detail-redirect/who-
- 345 wer9635-401-419
- 2. Mann S, Frasca K, Scherrer S, Henao-Martínez AF, Newman S, Ramanan P, et al. A Review
- of Leishmaniasis: Current Knowledge and Future Directions. Curr Trop Med Rep.
- 348 2021;8(2):121–32.
- 3. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis
- and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases
- 351 Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene
- 352 (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):e202–64.
- 4. Mathison BA, Bradley BT. Review of the Clinical Presentation, Pathology, Diagnosis, and
- Treatment of Leishmaniasis. Lab Med. 2022 Dec 5:lmac134.
- 5. Goto H, Lindoso JAL. Current diagnosis and treatment of cutaneous and mucocutaneous
- leishmaniasis. Expert Rev Anti Infect Ther. 2010 Apr 1;8(4):419–33.
- 6. Van der Auwera G, Ravel C, Verweij JJ, Bart A, Schönian G, Felger I. Evaluation of Four
- 358 Single-Locus Markers for Leishmania Species Discrimination by Sequencing. J Clin
- 359 Microbiol. 2014 Apr;52(4):1098–104.
- 7. Fernandes O, Murthy VK, Kurath U, Degrave WM, Campbell DA. Mini-exon gene variation
- in human pathogenic Leishmania species. Mol Biochem Parasitol. 1994 Aug 1;66(2):261–71.
- 362 8. World Health Organization. Global leishmaniasis update, 2006–2015: a turning point in
- leishmaniasis surveillance. Wkly Epidemiol Rec [Internet]. 2017 Sep 22;92. Available from:
- https://www.who.int/publications/i/item/who-wer9238
- 9. Wright NA, Davis LE, Aftergut KS, Parrish CA, Cockerell CJ. Cutaneous leishmaniasis in
- Texas: A northern spread of endemic areas. J Am Acad Dermatol. 2008 Apr 1;58(4):650–2.
- 367 10. Clarke CF, Bradley KK, Wright JH, Glowicz J. Case report: Emergence of autochthonous
- cutaneous leishmaniasis in northeastern Texas and southeastern Oklahoma. Am J Trop Med
- 369 Hyg. 2013 Jan;88(1):157–61.
- 370 11. Stahlman S, Williams VF, Taubman SB. Incident diagnoses of leishmaniasis, active and
- 371 reserve components, U.S. Armed Forces, 2001-2016. MSMR. 2017 Feb;24(2):2–7.
- 372 12. Curtin JM, Aronson NE. Leishmaniasis in the United States: Emerging Issues in a Region
- of Low Endemicity. Microorganisms. 2021 Mar;9(3):578.
- 374 13. McIlwee BE, Weis SE, Hosler GA. Incidence of Endemic Human Cutaneous
- Leishmaniasis in the United States. JAMA Dermatol. 2018 Sep 1;154(9):1032–9.

- 376 14. Prevention CC for DC and. CDC Leishmaniasis Resources for Health Professionals
- [Internet]. 2022 [cited 2022 Nov 23]. Available from:
- 378 https://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html
- 379 15. Lieberman JA, Bryan A, Mays JA, Stephens K, Kurosawa K, Mathias PC, et al. High
- Clinical Impact of Broad-Range Fungal PCR in Suspected Fungal Sinusitis. J Clin Microbiol.
- 381 2021 Aug 18;JCM0095521.
- 382 16. McCormick DW, Rassoulian-Barrett SL, Hoogestraat DR, Salipante SJ, SenGupta D,
- Dietrich EA, et al. Bartonella spp. Infections Identified by Molecular Methods, United States.
- 384 Emerg Infect Dis. 2023 Mar;29(3):467–76.
- 385 17. R Core Team. R: A Language and Environment for Statistical Computing [Internet].
- Vienna, Austria: R Foundation for Statistical Computing; 2022. Available from:
- 387 https://www.R-project.org/
- 388 18. Lorenzo PD. usmap: US Maps Including Alaska and Hawaii [Internet]. 2022 [cited 2022
- Nov 29]. Available from: https://CRAN.R-project.org/package=usmap
- 390 19. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome
- 391 to the Tidyverse. J Open Source Softw. 2019 Nov 21;4(43):1686.
- 392 20. Wilke CO. cowplot: Streamlined Plot Theme and Plot Annotations for "ggplot2"
- [Internet]. 2020 [cited 2022 Nov 29]. Available from: https://CRAN.R-
- 394 project.org/package=cowplot
- 395 21. Wickham H. ggplot2: Elegant Graphics for Data Analysis. [Internet]. Springer-Verlag
- New York; Available from: https://ggplot2.tidyverse.org
- 397 22. GraphPad Software [Internet]. [cited 2023 Feb 4]. Available from:
- 398 https://www.graphpad.com/quickcalcs/
- 399 23. Okonechnikov K, Golosova O, Fursov M, the UGENE team. Unipro UGENE: a unified
- 400 bioinformatics toolkit. Bioinformatics. 2012 Apr 15;28(8):1166–7.
- 401 24. Trifinopoulos J, Nguyen LT, von Haeseler A, Minh BQ. W-IQ-TREE: a fast online
- 402 phylogenetic tool for maximum likelihood analysis. Nucleic Acids Res. 2016 Jul
- 403 8;44(W1):W232–5.
- 404 25. Yu G. Using ggtree to Visualize Data on Tree-Like Structures. Curr Protoc Bioinforma.
- 405 2020;69(1):e96.
- 406 26. Guyard A, Boyez A, Pujals A, Robe C, Tran Van Nhieu J, Allory Y, et al. DNA degrades
- during storage in formalin-fixed and paraffin-embedded tissue blocks. Virchows Arch Int J
- 408 Pathol. 2017 Oct;471(4):491–500.

- 409 27. Chaara D, Ravel C, Bañuls AL, Haouas N, Lami P, Talignani L, et al. Evolutionary
- 410 history of Leishmania killicki (synonymous Leishmania tropica) and taxonomic implications.
- 411 Parasit Vectors. 2015 Apr 1;8(1):198.
- 412 28. Boggild AK, Caumes E, Grobusch MP, Schwartz E, Hynes NA, Libman M, et al.
- 413 Cutaneous and mucocutaneous leishmaniasis in travellers and migrants: a 20-year
- GeoSentinel Surveillance Network analysis. J Travel Med. 2019 Dec 23;26(8):taz055.
- 415 29. Herwaldt BL, Stokes SL, Juranek DD. American Cutaneous Leishmaniasis in U.S.
- 416 Travelers. Ann Intern Med. 1993 May 15;118(10):779–84.
- 417 30. Melby PC, Kreutzer RD, McMahon-Pratt D, Gam AA, Neva FA. Cutaneous
- leishmaniasis: review of 59 cases seen at the National Institutes of Health. Clin Infect Dis Off
- 419 Publ Infect Dis Soc Am. 1992 Dec;15(6):924–37.
- 420 31. Karimkhani C, Wanga V, Coffeng LE, Naghavi P, Dellavalle RP, Naghavi M. Global
- burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of
- 422 Disease Study 2013. Lancet Infect Dis. 2016 May 1;16(5):584–91.
- 423 32. Douvoyiannis M, Khromachou T, Byers N, Hargreaves J, Murray HW. Cutaneous
- 424 Leishmaniasis in North Dakota. Clin Infect Dis. 2014 Sep 1;59(5):e73–5.
- 425 33. Ganjaei KG, Lawton K, Gaur S. Cutaneous Leishmaniasis in an American Adolescent
- 426 Returning From Israel. J Pediatr Infect Dis Soc. 2018 Aug 17;7(3):e178–81.
- 427 34. Lemieux A, Lagacé F, Billick K, Ndao M, Yansouni CP, Semret M, et al. Cutaneous
- leishmaniasis in travellers and migrants: a 10-year case series in a Canadian reference centre
- for tropical diseases. Can Med Assoc Open Access J. 2022 Apr 1;10(2):E546–53.
- 430 35. Briggs N, Wei BM, Ahuja C, Baker C, Foppiano Palacios C, Lee E, et al. Mucocutaneous
- Leishmaniasis in a Pregnant Immigrant. Open Forum Infect Dis. 2022 Aug 1;9(8):ofac360.
- 432 36. Murray HW, Eiras DP, Kirkman LA, Chai RL, Caplivski D. Case Report: Mucosal
- Leishmaniasis in New York City. Am J Trop Med Hyg. 2020 Mar 30;102(6):1319–22.
- 434 37. Tejura N, Kim E, Dever LL, Chew D. Case Report: Mucocutaneous Leishmaniasis
- Masquerading as Idiopathic Midline Granulomatous Disease. Am J Trop Med Hyg. 2019 Sep
- 436 23;101(5):1107–10.
- 437 38. Hu RVPF, Kent AD, Adams ER, van der Veer C, Sabajo LOA, Mans DRA, et al. First
- case of cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis in Suriname. Am
- 439 J Trop Med Hyg. 2012 May;86(5):825–7.
- 440 39. Mody RM, Lakhal-Naouar I, Sherwood JE, Koles NL, Shaw D, Bigley DP, et al.
- 441 Asymptomatic Visceral Leishmania infantum Infection in US Soldiers Deployed to Iraq. Clin
- 442 Infect Dis. 2019 May 30;68(12):2036–44.

- 443 40. Roelfsema JH, Nozari N, Herremans T, Kortbeek LM, Pinelli E. Evaluation and
- improvement of two PCR targets in molecular typing of clinical samples of Leishmania
- patients. Exp Parasitol. 2011 Jan 1;127(1):36–41.
- 446 41. Reyes-Uribe P, Pereira-dos-Santos T, De Jesus JB, Mesquita-Rodrigues C, Arevalo J,
- 447 Cupolillo E, et al. Comparative zymographic analysis of metallopeptidase of Leishmania
- 448 (Viannia) peruviana and Leishmania (Viannia) braziliensis isolates from Peru. Parasitol Int.
- 449 2012 Dec;61(4):513–9.
- 450 42. Species Typing in Dermal Leishmaniasis | Clinical Microbiology Reviews [Internet].
- 451 [cited 2022 Oct 4]. Available from: https://journals.asm.org/doi/10.1128/CMR.00104-
- 452 14?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
- 453 43. Kato H, Gomez EA, Seki C, Furumoto H, Martini-Robles L, Muzzio J, et al. PCR-RFLP
- analyses of Leishmania species causing cutaneous and mucocutaneous leishmaniasis revealed
- distribution of genetically complex strains with hybrid and mito-nuclear discordance in
- 456 Ecuador. PLoS Negl Trop Dis. 2019 May 6;13(5):e0007403.
- 457 44. Kato H, Cáceres AG, Gomez EA, Tabbabi A, Mizushima D, Yamamoto DS, et al.
- 458 Prevalence of Genetically Complex Leishmania Strains With Hybrid and Mito-Nuclear
- Discordance. Front Cell Infect Microbiol [Internet]. 2021 [cited 2022 Dec 13];11. Available
- from: https://www.frontiersin.org/articles/10.3389/fcimb.2021.625001
- 461 45. Mendonça MG, de Brito MEF, Rodrigues EHG, Bandeira V, Jardim ML, Abath FGC.
- Persistence of leishmania parasites in scars after clinical cure of American cutaneous
- leishmaniasis: is there a sterile cure? J Infect Dis. 2004 Mar 15;189(6):1018–23.
- 464 46. Walter Reed Army Institute of Research (WRAIR) > Collaborate > Leishmania
- Diagnostics Laboratory [Internet]. [cited 2022 Nov 30]. Available from:
- https://wrair.health.mil/Collaborate/Leishmania-Diagnostics-Laboratory/
- 467 47. González C, Wang O, Strutz SE, González-Salazar C, Sánchez-Cordero V, Sarkar S.
- 468 Climate change and risk of leishmaniasis in north america: predictions from ecological niche
- models of vector and reservoir species. PLoS Negl Trop Dis. 2010 Jan 19;4(1):e585.
- 470 Figures
- 471 Figure 1. Geographic distribution of patients whose specimens were submitted to our
- 472 laboratory for *Leishmania* testing from September 2021 to August 2022.





Figure 2. Cumulative number of specimens and cases from September 2021 to August

2022.








Figure 3. Specimen types submitted for *Leishmania* testing.









Figure 4. Taxonomic and epidemiologic characteristics of Leishmania mini-exon sequences.

485

486



489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

Figure legends Figure 1. Geographic distribution of patients whose specimens were submitted to our laboratory for *Leishmania* testing from September 2021 to August 2022. Not depicted in this figure: 1 case from Quebec, Canada, 1 case from Puerto Rico. 1 case from the Dominican Republic was submitted by an institution in Florida. (A) The number of patients tested by each state in the U.S. (B) The positivity rate per state during this time period. States shaded in grey did not submit any specimens. (C) The number of patients who tested positive for *Leishmania* by each state. (D) List of the top 15 states by total test volume. Figure 2. Cumulative number of specimens and cases from September 2021 to August **2022.** Cumulative testing showing (A) total and positive volume of patients and specimens during each month and (B) total and positive volume of fresh vs formalin-fixed paraffinembedded specimens during each month. Figure 3. Specimen types submitted for *Leishmania* testing. Number of negative and positive specimens submitted from (A) skin and oropharyngeal mucosa, (B) internal organs, and (C) body fluids and miscellaneous sites. NOS = Not otherwise specified, RP = retroperitoneal. Figure 4. Taxonomic and epidemiologic characteristics of *Leishmania* mini-exon sequences. (A) Detected mini-exon sequences are represented as L, first two letters of species name, sequence variant, and number of times detected. The five most abundant mini-exon alleles are marked with arrowheads. Tips are purple triangles. Bootstrap values >95% are indicated as solid black nodes and 85-95% as grey nodes with black borders. Reference sequences are displayed

with full species name and Genbank accession for mini-exon locus; *L. amazonensis* strain

UA301 is indicated by the corresponding mini-exon locus CP040130. X-axis scale is
substitutions per site. (B) Bars represent defined taxonomic descriptions of subgenus and species
complex, as well as possible subclades or specific species within each complex as determined by
mini-exon sequence similarity. (C) Epidemiologic associations, including geography and clinical
presentation. OWL = Old World *Leishmania*, NWL = New World *Leishmania*.

517 **Tables**

Characteristic	1CT1/P		(%) positive by characteristic	(%) positive out of total positive cases (n = 94)	
Total tested	186	94	(50.5)	-	
Age group					
< 20	30	19	(63.3)	(20.2)	
< 10	15	11	(73.3)	(11.7)	
20-39	60	34	(56.7)	(36.2)	
40-59	57	25	(43.9)	(26.6)	
60-79	35	15	(42.9)	(16.0)	
>_80	4	1	(25.0)	(1.1)	
Sex					
Male	107	60	(56.1)	(63.8)	
Female	76	32	(42.1)	(34.0)	
Unknown	3	2	(66.7)	(2.1)	
Travel history					
Travel history					
Migration	10	7	(70.0)	(7.4)	
Travel ≤6 months	21	17	(81.0)	(18.1)	
Travel >6 months	4	2	(50.0)	(2.1)	
Travel, timing not specified	13	7	(53.8)	(7.4)	
Military	1	1	(100.0)	(1.1)	
No travel history	1	0	(0)	(0)	
Unknown	136	60	(44.1)	(63.8)	

Table 1. Demographic characteristics of patients with positive Leishmania PCR results.

Table 2. Species identified

Leishmania species (n = 94)	# positive (%) _{2.1}	by mini-exon sequencing
Subgenus Viannia	0-1	of man enon sequencing
Leishmania braziliensis spp. complex	17 (18.1) 522	
Leishmania guyanensis spp. complex	53 (56.4) 523	
Leishmania lainsoni	1 (1.1) 524	
Subgenus Leishmania	525	
Leishmania donovani spp. complex	1 (1.1) $\begin{array}{c} 526 \\ 527 \end{array}$	
Leishmania major	$3 (3.2) \begin{array}{c} 327 \\ 528 \end{array}$	
Leishmania mexicana spp. complex	9 (9.6) 529	
Leishmania tropica spp. complex ^A	10 (10.6) 530	

^A One case was reported as *L. killicki*, a member of the *L. tropica* spp. complex.

Table 3. Clinical and histopathological correlation with test positivity

535

536

	Positive for <i>Leishmania</i> (%)
Specimen type (n = 218)	
Fresh tissue	39/111 (35.1)
FFPE	65/107 (60.7)
Total	104/218 (47.7)
Cases with ulcers or lesions on physical exam $(n = 186)$	
Yes	45/68 (66.1)
Unknown	49/118 (41.5)
Cases with histopathological findings	
Amastigotes reported	15/17 (88.2)
Staining suspicious for organisms	12/12 (100.0)
No organisms seen	27/61 (34.4)
Unknown	40/96 (41.7)

Supplemental Materials

Figure S1. Case volume and positivity by month of testing.




Figure S1. Number of negative and positive specimens submitted and tested during each month of the study period. Negative cases are in gold; positive cases in purple.

Figure S2. Age Distribution of Patients Tested for Leishmaniasis.

562

563 564




Figure S2. Number of patients tested by indicated age range (X-axis). Negative cases are in gold; positive cases in purple.

Table S1. Test performance and validation

568

Specimen number	Specimen type	Reference identification	Leishmania PCR identification	Agreement
1	Cultured strain	L. donovani	L. donovani spp. complex	Yes
2	Cultured strain	L. major	L. major	Yes
3	Cultured strain	L. aethiopica	L. aethiopica	Yes
4	Cultured strain	L. chagasi	L. donovani spp. complex	Yes
5	Cultured strain	L. guyanensis	L. guyanensis	Yes
6	Genomic DNA	L. tropica	L. tropica	Yes
7	Cultured strain	L. panamensis	L. guyanensis/L. panemensis	Yes
8	Cultured strain	L. amazonensis	L. amazonensis	Yes
9	Patient specimen FFPE	L. tropica	L. tropica	Yes
10	Patient specimen FFPE	L. braziliensis	L. braziliensis	Yes
11	Patient specimen FFPE	L. braziliensis	L. braziliensis	Yes
12	Patient specimen FFPE	L. braziliensis	L. braziliensis	Yes
13	Patient specimen FFPE	L. braziliensis	Not detected	No
14	Patient specimen FFPE	L. braziliensis	L. braziliensis	Yes
15	Patient specimen FFPE	L. braziliensis	L. braziliensis	Yes
16	Patient specimen FFPE	L. braziliensis	Not detected	No
17	Patient specimen FFPE	Leishmania sp.	L. chagasi/L. infantum	Yes
18	Patient specimen tissue	Leishmania sp.	L. guyanensis/L. panamensis	Yes
19	Patient specimen tissue	Leishmania sp.	L. guyanensis/L. panamensis	Yes
20	Patient specimen FFPE	Leishmania sp.	L. guyanensis/L. panamensis	Yes
21	Patient specimen tissue	Leishmania sp.	L. braziliensis/L. peruviana	Yes
22	Patient specimen fluid	Pneumocystis jiroveci	Not detected	Yes
23	Patient specimen fluid	Pneumocystis jiroveci	Not detected	Yes

24	Patient specimen tissue	Toxoplasma gondii	Not detected	Yes
25	Patient specimen tissue	Toxoplasma gondii	Not detected	Yes
26	Patient specimen tissue	Histoplasma capsulatum	Not detected	Yes
27	Patient specimen tissue	Histoplasma capsulatum	Not detected	Yes
28	Patient specimen FFPE	Histoplasma capsulatum	Not detected	Yes
29	Patient specimen fluid	Histoplasma capsulatum	Not detected	Yes
30	Patient specimen fluid	Candida albicans	Not detected	Yes
31	Patient specimen FFPE	Candida tropicalis	Not detected	Yes
32	Patient specimen fluid	Candida glabrata	Not detected	Yes
33	Patient specimen tissue	Sporothrix schenckii	Not detected	Yes
34	Patient specimen tissue	Aspergillus fumigatus	Not detected	Yes
35	Patient specimen FFPE	Aspergillus fumigatus	Not detected	Yes
36	Patient specimen tissue	Escherichia coli	Not detected	Yes
37	Patient specimen FFPE	Escherichia coli	Not detected	Yes
38	Patient specimen tissue	Pseudomonas aeruginosa	Not detected	Yes
39	Patient specimen tissue	Pseudomonas aeruginosa	Not detected	Yes
40	Patient specimen fluid	Staphylococcus aureus	Not detected	Yes
41	Patient specimen fluid	Staphylococcus aureus	Not detected	Yes
42	Patient specimen tissue	Streptococcus pneumoniae	Not detected	Yes
43	Patient specimen fluid	Streptococcus pneumoniae	Not detected	Yes

Table S2. Limit of detection

572

573

574

575

Species	Replicates positive at 1 genome/reaction
L. major	4/4
L. donovani	2/2
L. aethiopica	6/6
L. chagasi	6/6
L. tropica	4/4
L. panamensis	6/6
L. amazonensis	4/4
Total	32/32 (100%)

Table S3. Species identified by travel history

Country	Travel history < 6 mo.	Travel history > 6 mo.	Travel history, timing not specified	Migration	Militar y	Species detected
Central Americ	a					,
Belize	1					L. mexicana spp. complex (1)
Costa Rica	9		3			L. guyanensis spp. complex (11) L. braziliensis spp. complex (1)
Guatemala				1		L. braziliensis spp. complex (1)
Panama	1					L. guyanensis spp. complex (1)
Not otherwise specified			1			L. guyanensis spp. complex (1)
North America						
Mexico			1			L. mexicana (1)
South America						
Bolivia		1 ^A				L. braziliensis spp. complex (1)
Ecuador	2			1		L. guyanensis spp. complex (2) L. lainsoni (1)
Peru	1					L. braziliensis spp. complex (1)
Guyana		1				L. braziliensis spp. complex (1)
Venezuela				1		L. guyanensis spp. complex (1)
Middle East		ı	ı	1	1	

Afghanistan			1		L. tropica spp. complex (1)
Yemen	1				L. tropica spp. complex (1)
Africa					
Nigeria			1		L. guyanensis spp. complex (1)
Tunisia	1 ^B				L. killicki (1)
Other					
Travel noted, location unknown		1		1	L. major (1) L. braziliensis spp. complex (1)
Multiple endemic countries	1	1	2		L. guyanensis spp. complex (4)

^A Patient had documented infection after traveling in 2016 and had relapse of mucocutaneous leishmaniasis in 2022.

Table S4. Repeat testing

	585
Category	# patients
I. Multiple specimens negative	
a. 30+ days apart	3
b. Within 30 days	6
II. Multiple specimens positive within 30 days	
a. Different sites	4
b. Similar or same site	4
c. Unknown if sites are same or different	1
III. Initial positive specimen, subsequent negative specimen 30+ days later	3
IV. Multiple specimens positive 30+ days apart	1

^B Patient lived in Tunisia prior to coming to the U.S. and developed infection after a recent return visit.

Table S5: Metadata for Positive Cases

Study				Location		Mini-Exon	
Number ¹	Age	Sex	Species Identified	Acquired	Anatomic Site	Sequence	Allele Comments
200jB	30-34	M	L. braziliensis spp. complex	Not provided	Skin, Arm	Lbr_B-04	
3NY5V	40-44	M	L. braziliensis spp. complex	Not provided	Skin, Foot	Lbr_E-01	Previously unreported
3pZcY	15-19	M	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_F-01	Previously unreported
4AGIK	15-19	M	L. mexicana spp. complex	Not provided	Skin, Face	Lme_A-04	
4qXFx	60-64	M	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
4qXFx	60-64	M	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
4Tpmt	65-69	M	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_A-39	
5d8uv	50-54	M	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
5N4y7	25-29	M	L. guyanensis spp. complex	Not provided	Skin, Back	Lgu_E-02	
6DvUz	25-29	M	L. guyanensis spp. complex	Not provided	Skin, Hand	Lgu_D-03	
71Qur	30-34	M	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_B-07	
7lE4E	25-29	M	L. guyanensis spp. complex	Costa Rica	Skin, Leg	Lgu_A-39	
7nBtA	30-34	M	L. guyanensis spp. complex	Not provided	Skin, Face	Lgu_C-03	Previously unreported
9s3Zi	20-24	M	L. mexicana spp. complex	Not provided	Skin, Leg	Lme_B-03	
A1UVR	50-54	F	L. guyanensis spp. complex	Costa Rica	Skin, Hand	Lgu_A-39	
aFZBo	50-54	M	L. guyanensis spp. complex	Nigeria	Skin, Leg	Lgu_B-07	
ahPNz	15-19	M	L. guyanensis spp. complex	Multiple endemic countries: Costa Rica OR Belize	Skin, Chest	Lgu_A-39	
ahPNz	15-19	M	L. guyanensis spp. complex	Multiple endemic countries: Costa Rica OR Belize	Skin, Elbow	Lgu_A-39	
aNewR	5-9	F	L. major	Not provided	Skin, NOS	Lma_B-01	
ASuG7	55-59	M	L. guyanensis spp. complex	Costa Rica	Skin, Leg	Lgu_A-39	
Bb1ZK	50-54		L. mexicana spp. complex	Not provided	Skin, Leg	Lme_B-03	

bJ2RQ	65-69	M	L. guyanensis spp. complex	Not provided	Skin, NOS	Lgu_C-03	Previously unreported
bVQ6L	5-9	M	L. tropica spp. complex	Afghanistan	Skin, Face	Ltr_A-01	Previously unreported
bz3MQ	25-29	M	L. guyanensis spp. complex	Costa Rica	Skin, NOS	Lgu_A-39	
cvuHr	40-44	U	L. lainsoni	Ecuador	Skin, Arm	Lla_A-01	Previously unreported
dDNho	< 5	M	L. tropica spp. complex	Not provided	Skin, Face	Ltr_H-01	Previously unreported
dl8Uh	< 5	F	L. guyanensis spp. complex	Panama	Skin, Leg	Lgu_A-39	
dOJ9R	35-39	M	L. braziliensis	Not provided	Skin, Knee	Lbr_F-01	Type 2 L. braziliensis
DqThk	< 5	F	L. mexicana spp. complex	Not provided	Skin, Face	Lme_D-01	Previously unreported
dxbWJ	20-24	M	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	ace
gdTX9	25-29	M	L. tropica spp. complex	Not provided	Skin, Hand	Ltr_B-01	Previously unreported
gSFeb	45-49	M	L. guyanensis spp. complex	Costa Rica	Skin, NOS	Lgu_A-39	able
hliza	40-44	M	L. guyanensis sppp. complex	Not provided	Skin, NOS	Lgu_D-03	ung
HswPn	>80	M	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	a a
ifG7T	75-79	M	L. braziliensis spp. complex	Costa Rica	Skin, Leg	Lbr_B-04)
j5uY1	30-34	M	L. braziliensis spp. complex	Bolivia	Mucosa, Nasal	Lbr_A-06	
JD1Fi	35-39	F	L. guyanensis spp. complex	Costa Rica	Skin, Arm	Lgu_A-39	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
JfPzu	35-39	M	L. guyanensis spp. complex	Not provided	Skin, Face	Lgu_A-39	4.0
JfPzu	35-39	M	L. guyanensis spp. complex	Not provided	Skin, Face	Lgu_A-39	nter
KaEnn	25-29	M	L. braziliensis spp. complex	Not provided	Skin, Nose	Lbr_B-04	natio
L7liP	40-44	M	L. braziliensis spp. complex	Guatemala	Skin, Nose	Lbr_C-01	Previously unreported
lqj5v	10-14	F	L. braziliensis spp. complex	Not provided	Mucosa, Nasal	Lbr_A-06	Cens
LY4kh	25-29	F	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_A-39	Ф
mj7LX	15-19	F	L. guyanensis spp. complex	Costa Rica	Skin, Knee	Lgu_A-39	
MNaNr	25-29	M	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_A-39	
MnFJU	20-24	F	L. braziliensis spp. complex	Not provided	Skin, Face	Lbr_J-01	
MQ3Iq	30-34	M	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_A-39	
MqS1M	< 5	F	L. tropica spp. complex	Not provided	Skin, Face	Ltr_J-01	
N58sC	30-34	M	L. braziliensis spp. complex	Not provided	Skin, NOS	Lbr_A-06	

Ngbt9	10-14	F	L. tropica spp. complex	Not provided	Skin, Face	Ltr F-01	Previously unreported
nhxid	60-64	F	L. braziliensis spp. complex	Not provided	Skin, Face	Lbr_A-06	J 1
nLIzV	5-9	F	L. tropica spp. complex	Yemen	Skin, Nasal	 Ltr_D-01	Previously unreported
OkKEs	45-49	F	L. guyanensis spp. complex	Costa Rica	Skin, Leg	Lgu_A-39	<u>, , , , , , , , , , , , , , , , , , , </u>
OkKEs	45-49	F	L. guyanensis spp. complex	Costa Rica	Skin, Leg	Lgu_A-39	
oYo7a	40-44	F	L. guyanensis spp. complex	Costa Rica	Skin, Face	Lgu_A-39	
paee2	25-29	U	L. guyanensis spp. complex	Not provided	Skin, NOS	Lgu_B-07	
pmg22	40-44	M	L. tropica spp. complex	Tunisia	Skin, Arm	Ltr_G-01	
PRu3I	35-39	M	L. guyanensis spp. complex	Costa Rica	Skin, Arm	Lgu_I-01	
PRu3I	35-39	M	L. guyanensis spp. complex	Costa Rica	Skin, Ear	Lgu_H-01	Previously unreported
q6Y0m	30-34	F	L. mexicana spp. complex	Belize	Skin, Arm	Lme_A-04	
qljLb	70-74	M	L. guyanensis spp. complex	Not provided	Skin, Buccal	Lgu_A-39	
QlW8W	55-59	F	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
QsNa7	70-74	U	L. mexicana spp. complex	Mexico (Yucatan)	Skin, Arm	Lme_A-04	
QsNa7	70-74	M	L. mexicana spp. complex	Mexico (Yucatan)	Skin, Arm	Lme_A-04	
r7Bif	75-79	M	L. guyanensis spp. complex	Ecuador	Skin, Ear	Lgu_G-01	Previously unreported
r7Bif	75-79	M	Leishmania sp, NOS	Ecuador	Skin, Face	Lsp_A-01	Previously unreported
rHGuZ	35-39	F	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
rUtEq	10-14	F	L. guyanensis spp. complex	Venezuela	Skin, Leg	Lgu_B-07	
RZyXs	40-44	M	L. donovani/infantum/chagasi spp. complex	Not provided	Lymph Node, inguinal	Ldo_A-01	
SHAjS	25-29	M	L. tropica spp. complex	Not provided	Skin, NOS	Ltr_C-01	Previously unreported
SrbZI	35-39	M	L. guyanensis spp. complex	Not provided	Skin, Face	Lgu_J-01	
				Multiple endemic countries: Panama OR Honduras OR Nicaragua OR Colombia OR			
tnbbZ	35-39	M	L. guyanensis spp. complex	Guatemala	Skin, Hand	Lgu_B-07	

medRxiv preprint doi: https://doi.org/10.1101/2023.05.23.23290303; this version posted May 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

	me (
	which
ed	y preg
	orint o
1	cert
	ified
	by k
	org/10 eer re
	3 ₹. ⊆
	101/2 ew) is ade a
	023. s the availa
	3.05.2 e auth ilable i
	3.232 lor/fui undei
1	329030 under, o er a CC
ed	03; tl
1	his vo
ed	ersio grar
	n pos
1	osted d medl
ed	d May dRxiv mation
	/ 28, 2 / a lice
	023. 9nse t
	The to di:
	cop) splay
	/right
	t hold
ed	der for rint ir
	or this
	s prep petuit
	reprint tuity.

					T		
U19Vi	10-14	M	L. guyanensis spp. complex	Not provided	Skin, Hand	Lgu_A-39	
uf2WQ	60-64	F	L. braziliensis sppp. complex	Not provided	Skin, Hand	Lbr_I-01	Previously unreported
UMVeK	45-49	M	L. braziliensis spp. complex	Not provided	Mucosa, Tonsil	Lbr_D-01	
					Mucosa,		Reported once, from
UMVeK	45-49	M	L. braziliensis spp. complex	Not provided	Epiglottis	Lbr_H-01	Suriname
UrDnb	45-49	F	L. guyanensis spp. complex	Not provided	Skin, Face	Lgu_A-39	
usKjM	35-39	F	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
usKjM	35-39	F	L. guyanensis spp. complex	Not provided	Skin, Hand	Lgu_A-39	
viGq0	70-74	M	L. braziliensis spp. complex	Not provided	Skin, Hand	Lbr_B-04	
VPME3	60-64	M	L. mexicana spp. complex	Not provided	Skin, Face	Lme_C-01	
vtbyX	50-54	M	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_A-39	
VXYJc	35-39	M	L. guyanensis spp. complex	Not provided	Skin, NOS	Lgu_A-39	
VXYJc	35-39	M	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
W2523	45-49	F	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_K-01	Previously unreported
WdF6F	25-29	M	L. major	Not provided	Skin, Leg	Lma_A-01	
wNI9E	40-44	F	L. guyanensis spp. complex	Not provided	Skin, Elbow	Lgu_C-03	Previously unreported
WPNzg	60-64	M	L. guyanensis spp. complex	Central America	Skin, Back	Lgu_E-02	
XATsT	5-9	F	L. guyanensis spp. complex	Ecuador	Skin, Arm	Lgu_A-39	
XEnxF	< 5	M	L. tropica spp. complex	Not provided	Skin, Face	Ltr_I-01	Previously unreported
				Multiple endemic			
MIG B	50.54	3.7		countries: Panama	CI: IX	1 D 07	
XkSqR	50-54	M	L. guyanensis spp. complex	OR Mexico	Skin, Knee	Lgu_B-07	
XpFLs	65-69	M	L. mexicana spp. complex	Not provided	Skin, Face	Lme_B-03	
yfxW2	60-64	M	L. braziliensis spp. complex	Not provided	Skin, Arm	Lbr_A-06	
YfZoO	< 5	F	L. guyanensis spp. complex	Not provided	Skin, Knee	Lgu_B-07	
YHq5X	45-49	F	L. tropica spp. complex	Not provided	Skin, Chest	Ltr_E-01	
yqxw6	55-59	F	L. mexicana spp. complex	Not provided	Skin, Leg	Lme_E-01	Previously unreported
YRcvQ	25-29	M	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_A-39	

	랓	Š.
	was	prep
	ot	Tint (
	cer	<u>ö</u> .
	ffie	http
	٥	s://d
	/ pee	rint doi: https://doi.org/
÷.	ē	10.
3	è	110
5	is	1/20
5	the	23.
5	auth	05.2
5	or/	3.2
2	pund	329
3	er, 1	300
9	₽	<u>Ş;</u> ∰
2	ha	is <
2	s gra	ersic
	s granted	ersion p
	s granted me	ersion poste
	s granted medR:	10.1101/2023.05.23.23290303; this version posted M
	s granted medRxiv a	ersion posted May 2
	s granted medRxiv a lice	ersion posted May 28, 2
	s granted medRxiv a license	ersion posted May 28, 2023
	s granted medRxiv a license to	ersion posted May 28, 2023. Th
	s granted medRxiv a license to disp	ersion posted May 28, 2023. The co
	s granted medRxiv a license to display t	ersion posted May 28, 2023. The copyr
	s granted medRxiv a license to display the p	ersion posted May 28, 2023. The copyright
	s granted medRxiv a license to display the prep	nt doi: https://doi.org/10.1101/2023.05.23.23290303; this version posted May 28, 2023. The copyright hold
	s granted medRxiv a license to display the preprint .	ersion posted May 28, 2023. The copyright holder f
	s granted medRxiv a license to display the preprint in pe	ersion posted May 28, 2023. The copyright holder for the
	certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpe	ersion posted May 28, 2023. The copyright holder for this p
, and a contraction of the contr	s granted medRxiv a license to display the preprint in perpetuity	ersion posted May 28, 2023. The copyright holder for this prepr
	s granted medRxiv a license to display the preprint in perpetuity.	ersion posted May 28, 2023. The copyright holder for this preprint

				Multiple endemic			
				countries: Central			
				& South America			
				(including			
yv1zu	5-9	F	L. guyanensis spp. complex	Amazon region)	Skin, Arm	Lgu_D-03	
				Not provided	Skin, Arm and		
zDVRa	40-44	M	L. major	(suspected)	Flank	Lma_C-01	
zNB0C	20-24	M	L. braziliensis	Peru	Skin, Foot	Lbr_G-01	Type 2 L. braziliensis
zOa4f	35-39	F	L. guyanensis spp. complex	Not provided	Skin, Hand	Lgu_A-39	
zr4An	55-59	M	L. guyanensis spp. complex	Costa Rica	Skin, Leg	Lgu_A-39	
zSazm	25-29	F	L. guyanensis spp. complex	Not provided	Skin, Hand	Lgu_A-39	
					Mucosa,		
VmHYS	65-69	M	L. braziliensis spp. complex	Guyana	Oropharynx	Lbr_A-06	

¹Study number is a random 6-digit alphanumeric string which provides a unique, anonymous key for each patient.